SUMMARY. The extent of lipoprotein glycation was assessed in 82 patients diagnosed as diabetes mellitus type II. Glycated lipoprotein levels in serum were determined by agarose gel film electrophoresis in 48 non-diabetic control subjects, 56 diabetics with complications and 26 diabetics with no complications. All glycated lipoproteins were higher in the patients when the diabetics were compared to the control group, but glycated very low-density lipoprotein (VLDL) was the only glycated lipoprotein fraction that was observed to be higher in the diabetic patients with complications compared to the patients without complications (P<O·OI) . Triglycerides and VLDLcholesterol were also increased in the diabetics, but there was no significant difference in these variables when the patients without complications were compared to the control subjects. There was no difference in total cholesterol and low-density lipoprotein (LDL)-cholesterollevels of the diabetic patients compared to the controls.
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Hyperglycaemia in diabetes is accompanied by posttranslational, nonenzymatic glycation of plasma and cellular proteins.' Increased nonenzymatic glycation of proteins has been implicated in the aetiology of several complications in diabetes mellitus, including cataract formation, connective tissue abnormalities, and macrovascular disease.i" Many recent studies have concentrated on the glycation of lipoprotein particles, since lipoprotein abnormalities are closely related to the development of macrovascular disease, which is the major cause of death in about 80070 of diabetic patients.'-3,5,6 It has been proposed that at least some of the abnormalities of low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) metabolism in diabetic subjects may be attributed to changes in lipoprotein function brought about by nonenzymatic glycation of their apoproteins.l-?
Even though lipoprotein glycation is closely related to the development of diabetic complications, the clinical significance of these findings is unclear because the extent of lipoprotein glycation Correspondence: Dr Aysenur Yegin, occuring in vivo in diabetic patients has not been investigated in detail. 5 One reason for this is that the methods for analysis of glycated lipoproteins are complex and time-consuming. In this study, we compared the extent of lipoprotein glycation in type II diabetic patients with or without complications using a simple electrophoretic method modified from the procedure originally described by Kobayashi et al. 8 
METHODS

Subjects
The diabetic group (n = 82) consisted of outpatients who were undergoing diet or oral antidiabetic treatment at the Mediterranean University School of Medicine Hospital. They had been classified as having type II diabetes mellitus according to the criteria established by the National Diabetes Data Group." The patients were divided into two groups, those without any long-term complications (n = 26) and those with clinically confirmed complications (n = 56).
Of 56 patients: 15 had diabetic cataracts either in one or both eyes; 16 had retinopathy; 11 peripheral neuropathy; 29 hypertension; 15 had 459 atherosclerotic heart disease; and 26 had no complications. Patients with retinopathy were examined by fundoscopy with dilated pupils and had either background or proliferative retinopathy. For the assessment of cataract formation, a slit lamp was used after pupillary dilation. The diagnosis of atherosclerotic heart disease was made by clinical symptoms of angina and documented myocardial infarction and was confirmed by cardiac angiography. Hypertension was defined as the use of anti-hypertensive drugs or actual systolic blood pressure> 160 mmHg or diastolic blood pressure > 95 mmHg. Neuropathy was defined as the absence of at least one Achilles tendon reflex.
The non-diabetic control group comprised 48 ambulant volunteers, who attended the laboratory for blood testing but who had no history of diabetes or any other major illness. In these subjects, diabetes was excluded on the basis of fasting serum glucose levels.
Blood was drawn from overnight fasting (10-12 h) patients and control subjects into a tube with no anticoagulant and a separate tube containing heparin for the analysis of glycated haemoglobin. After the blood had clotted, the tube without anticoagulant was centrifuged at 1500 x g for 10 min and the supernatant serum was separated. After analysis for serum glucose, total cholesterol, triglyceride, and high-density lipoproteins (HDL)-cholesterol levels, the remaining serum was stored at + 4DC until use. Fructosamine and glycated lipoprotein analyses were carried out within a week.
Glycated lipoproteins
The extent of lipoprotein glycation in serum was assessed by Kobayashi's agarose gel film electrophoresis method! with a modified detection procedure. Four microlitres of serum were applied to commercial agarose gel film (Titan Gel Agarose Electrophoresis Systems-Lipoprotein Kit, Helena Laboratories, Beaumont TX, USA, Catatalogue No. 3045) and electrophoresed at 60 V for 40 min in sodium barbiturate buffer (pH 8· 6). The gel was then incubated in 10 mL 5 mmol/L nitroblue tetrazolium (NBT; Sigma, St Louis, MO, USA, Catalogue No. N-6876) for 20 min at room temperature, tightly wrapped with parafilm and kept at 35°C for 16 h. The gel film was rinsed twice in 60: 40 (vIv) methanol: distilled water mixture for 10 min, and then dried at 90°C for 20 min. The four bands Ann Clin Biochem 1995: 32 (glycated LDL, glycated VLDL, glycated HDL, and glycated albumin) visualized by NBT are shown in Fig. I . The glycated lipoprotein and glycated albumin bands were scanned at 545 nm with a densitometer (Gelman Densitometer DCD-16, Gelman Sciences, Ann Arbor, MI, USA) to quantify the relative amounts of the individual bands. These proportions were represented as the percentage of the total area under the scanned profile attributed to each peak. Each concentration was calculated from the percentage multiplied by the value for total serum fructosamine (p.mol/L). S Within-run and run-to-run reproducibilities (coefficients of variation, CVs) for the assay of glycated albumin and glycated lipoproteins by modified agarose gel film electrophoresis were 3·40/0 and 5· 1% (glycated albumin), 2· 8% and 9· 8% (glycated a-lipoprotein), 9· I % and 10.6% (glycated pre (3lipoprotein) and 9·3 % and II . 3% (glycated (3 lipoprotein), respectively (n = 10).
Fructosamine assay
We measured serum fructosamine by the method of Johnson et 01. 10 with the Boehringer (Mannheim, Germany) assay kit.
Glycated haemoglobin Glycated haemoglobin was measured by affinity gel chromatography using the Isolab Glyc-Affin System (ISOLAB Inc., Akron, OH, USA).
Other methods
Concentrations of fasting glucose, total-and HDL-cholesterol, and triglyceride in serum were assayed by using Dart reagents with an automated clinical analyser (Dacos Autoanalyzer, Coulter, Hialeah, FL, USA). LDL-cholesterol was calculated by the Friedewald formula: LDL-cholesterol = total-cholesterol-(HDL-cholesterol) -(VLDLcholesterol). I 1 VLDL-cholesterol was calculated by the formula: VLDL-cholesterol = triglyceride/ 2· 22. 11 , 12 All patients had triglyceride levels below 4· 5 mmol/L, which is the cut-off value above which the calculation of LDL concentration is not permissible.U'F
Statistical methods
Statistical analyses were carried out with the Microstat Statistical Program (Ecosoft Inc, Indianapolis, IN, USA; 1984) and the significance of differences between diabetics and normal controls with respect to each of the variables measured was assessed by Student's t test.
RESULTS
FIGURE I. The four bands on the agarose gel film visualized by nitro blue tetrazolium: (glycated low-density lipoprotein (LDL); very low-density lipoprotein (VLDL); high-density lipoprotein (HDL); and albumin
). An example of a densitometric scan is also given.
The data obtained for fasting serum glucose. glycated haemoglobin and serum fructosamine, total cholesterol. LDL-. VLDL-. and HDLcholesterol. triglyceride. glycated lipoproteins and glycated albumin are shown in Table 1 for both the control subjects and the patients. Clinical details of the patients are shown in Table 2 .
The glycaemic control parameters. namely fasting serum glucose. glycated haemoglobin and fructosamine, were significantly increased in all the diabetic patients without complications when compared to the controls (fable I). Fasting serum glucose and glycated haemoglobin concentrations were also significantly higher (P<O·OI) in patients with complications compared to patients without complications. but the difference between fructosamine levels in these two groups did not reach statistical significance. This might be important when comparing the values for glycated-Iipoproteins.
Glycated lipoprotein concentrations (glycated HDL. LDL, and VLDL) were all significantly increased in diabetics with or without complications when compared to the control subjects (fable I) but the only glycated lipoprotein fraction which showed a significant (P<O'OI) increase in patients with complications was glycated VLDL. Since serum fructosamine was the basis for estimating the glycated VLDL value and this parameter was not significantly increased in the diabetic group with complications over those without complications, the significant increase in glycated VLDL of this group compared to the diabetics without complications might be more important.
The only lipid parameters that were significantly higher in the whole diabetic group (n = 82) compared to controls were triglycerides and VLDL-cholesterol (P<0'05 for both).
DISCUSSION
The effects of non-enzymatic glycation on lipoprotein particles have been intensively studied.I-v'! It has been suggested that low affinity of the apoprotein B receptors of glycated-LDL would contribute to the increase in plasma cholesterol levels in diabetics. 14 However, total-and LDL-cholesterol concentrations have not always been found to be elevated in diabetic patients.r':"" Our results also show -no significant difference in these parameters when the controls and the patients are compared (Table I) .
On the other hand, glycated LDL is significantly higher in the whole diabetic group (n = 82), but we found no significant difference when diabetics with and without complications are compared. In contrast, Kobayashi et al., in one of the few reports to quantify glycated lipoproteins, found an increase in glycated LDL values in diabetics with complications compared to those without. 8 The same electrophoretic method was used for quantitation in both studies and we did see a small increase in the glycated LDL of the diabetics without complications, but this did not reach statistical significance. In contrast to total and LDL-cholesterol concentrations, serum triglycerides and VLDLcholesterol have always been found to be increased in diabetics in previous epidemiological Ann ctt« Biochem 1995: 32 studies. 6 -8 , 14-23 This was confirmed in our study, for diabetics with complications against controls (P<0·05 for both) and against diabetics without complications (P<0'05 for both).
All the glycated lipoprotein fractions were significantly increased in both diabetic groups when compared to control subjects (Table I) . However, only glycated VLDL is significantly increased (P<O'OI) in the diabetic group with complications when compared with those without complications. In contrast, Kobayashi et at. found no significant difference in glycated VLDL levels between diabetics with and without complications." However, glycated VLDL levels were increased in the whole diabetic group compared to the controls. The authors explain this increase merely by the well-known increase in VLDL in diabetic patients," but our data show that the increase in glycated VLDL is not parallel to the increase in serum VLDLcholesterol levels. For example, there is no increase in VLDL-cholesterol in the uncomplicated diabetic group compared to the control subjects, but glycated VLDL is considerably higher (P<O·Ol). However, this does not dismiss Kobayashi's explanation, because VLDL triglyceride concentrations are more important, and we have not measured this parameter. It must also be remembered that it is the apolipoproteins which become glycated and not the lipid component. Increased glycated VLDL might not necessarily parallel serum VLDL-cholesterol levels. There was no correlation between glycated VLDL and duration of diabetes (r= 0'1694, P>0·05).
CONCLUSION
We have observed an aSSOCiatIOn between VLDL glycation and the presence of diabetic complications.
